XML 29 R18.htm IDEA: XBRL DOCUMENT
v3.8.0.1

12. Restructuring Costs (Notes) | 3 Months Ended
--- | ---
Mar. 31, 2018
Restructuring Costs [Abstract] |
Restructuring and Related Activities Disclosure [Text Block] | 12. RESTRUCTURING COSTS Restructuring Costs for European Reorganization In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and other employee benefits for the three months ended March 31, 2018. The liability of $5.4 million as of March 31, 2018 consisted of $5.3 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets. The amounts recorded reflected in Cost of goods sold and in Selling, general and administrative expense in the Condensed Consolidated Statements of Income for the three months ended March 31, 2018 were both less than $0.1 million. The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):
|  | Life Science |  | Clinical Diagnostics |  | Total
Balance as of January 1, 2018 |  | $ | 2.2 |  |  | $ | 4.1 |  |  | $ | 6.3 |
Charged to expense |  | — |  |  | — |  |  | — |
Adjustment to expense |  | — |  |  | — |  |  | — |
Cash payments |  | (0.3 | ) |  | (0.7 | ) |  | (1.0 | )
Foreign currency translation losses |  | — |  |  | 0.1 |  |  | 0.1 |
Balance as of March 31, 2018 |  | $ | 1.9 |  |  | $ | 3.5 |  |  | $ | 5.4 |
Restructuring Costs for Termination of a Diagnostics Research and Development Project In December 2017, we announced the termination of a diagnostics research and development project in Europe, which is included in our Clinical Diagnostics segment's results of operations. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and employee benefits, and exit costs for the three months ended March 31, 2018. The amounts recorded reflected in Cost of goods sold, in Selling, general and administrative expense, and in Research and development expense in the Condensed Consolidated Statements of Income for the three months ended March 31, 2018 were all less than $0.1 million. The liability of $13.1 million as of March 31, 2018 consisted of $10.0 million recorded in Accrued payroll and employee benefits and $3.1 million recorded in Other current liabilities in the Condensed Consolidated Balance Sheets. The following table summarizes the activity for the termination of the diagnostics research and development project restructuring reserves for severance and exit costs (in millions):
|  | 2018
Balance as of January 1 |  | $ | 14.1 |
Charged to expense |  | — |
Adjustment to expense |  | — |
Cash payments |  | (1.3 | )
Foreign currency translation losses |  | 0.3 |
Balance as of March 31 |  | $ | 13.1 |

X
- Definition The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 420 -URI http://asc.fasb.org/topic&trid=2175745 + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RestructuringCostsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration